Earnings ·
Compass Pathways plc reported financial results for the three and six months ended June 30, 2026
CMPSCOMPASS Pathways plc
Compass Pathways plc reported financial results for the three and six months ended June 30, 2026. The company posted a net loss of $253.8 million ($1.88 per share) for Q2 and $162.6 million ($1.33 per share) for H1, driven primarily by non-cash fair value adjustments on warrant liabilities totaling $205.6 million in the quarter. Cash and cash equivalents rose to $433.3 million from $149.6 million at year-end 2025. R&D expenses decreased to $29.2 million for Q2, while G&A increased to $23.2 million due to commercial preparation costs. The company confirmed its rolling NDA submission is on track for completion in Q4 2026, with a commercial launch expected in the first half of 2027 subject to FDA approval and DEA rescheduling. Compass Pathways plc operates as a biotechnology company developing psychedelic-based treatments for mental health conditions.